Nuvectra is a neuromodulation medical device company focused on the development and commercialization of our neurostimulation technology platform for the treatment of various disorders through stimulation of tissues associated with the nervous system. The Company's neurostimulation technology platform has the capability to provide treatment to patients in several established neurostimulation markets, including spinal cord stimulation, sacral nerve stimulation, deep brain stimulation, and other emerging neurostimulation markets. Nuvectra's Algovita SCS system, or Algovita, is the first application of the Company's stimulation technology platform and is indicated for the treatment of chronic pain of the trunk and limbs.

Type
Public
HQ
Plano, US
Founded
2016
Size (employees)
89 (est)
Nuvectra Corporation was founded in 2016 and is headquartered in Plano, US
Report incorrect company information

Nuvectra Corporation Office Locations

Nuvectra Corporation has an office in Plano
Plano, US (HQ)
1100 5830 Granite Pkwy
Show all (1)
Report incorrect company information

Nuvectra Corporation Financials and Metrics

Nuvectra Corporation Financials

Nuvectra Corporation's revenue was reported to be $31.84 m in FY, 2017
USD

Revenue (Q1, 2018)

10.6 m

Gross profit (Q1, 2018)

5.8 m

Gross profit margin (Q1, 2018), %

54.5%

Net income (Q1, 2018)

(10.5 m)

EBIT (Q1, 2018)

(9.6 m)

Market capitalization (22-Jun-2018)

325.7 m

Closing share price (22-Jun-2018)

23

Cash (31-Mar-2018)

53.9 m

EV

310.2 m
Nuvectra Corporation's current market capitalization is $325.7 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

5.2 m12.5 m31.8 m

Revenue growth, %

139%

Cost of goods sold

3.4 m6.4 m15.9 m

Gross profit

1.9 m6.1 m16 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

2.1 m2.6 m3.8 m5 m7.2 m10.6 m

Cost of goods sold

1.1 m1.3 m1.6 m2.4 m3.5 m4.8 m

Gross profit

1 m1.3 m2.1 m2.6 m3.7 m5.8 m

Gross profit Margin, %

49%51%57%52%51%55%
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

202 k63.7 m28.2 m

Accounts Receivable

4.2 m

Inventories

24 k5.2 m5 m

Current Assets

764 k72.6 m45 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

90.3 m83.5 m75.6 m48.1 m34.4 m53.9 m

Inventories

4 m3.5 m4.5 m

Current Assets

92.1 m87.1 m79.7 m56.7 m44.1 m68.3 m

PP&E

5.2 m5.5 m6.6 m6.5 m6.3 m6 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(24.4 m)(38.4 m)(44.6 m)

Depreciation and Amortization

1.6 m

Inventories

(162 k)

Accounts Payable

(2.4 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(2 m)(10.7 m)(20.2 m)(13.1 m)(10.5 m)

Depreciation and Amortization

445 k

Inventories

4 m399 k

Accounts Payable

5.5 m5.8 m8.4 m5.9 m(1.4 m)
USDY, 2018

EV/EBIT

-32.2 x

EV/CFO

-31.6 x

Financial Leverage

1.8 x
Show all financial metrics

Nuvectra Corporation Operating Metrics

Nuvectra Corporation's Patent Applications was reported to be 132 in FY, 2016.
FY, 2016

Patent Applications

132

Patents Issued

265

Trademarks (foreign)

17

Trademarks Pending

31
Show all operating metrics

Nuvectra Corporation Revenue Breakdown

Embed Graph

Nuvectra Corporation revenue breakdown by business segment: 41.1% from NeuroNexus and 58.9% from Nuvectra

Report incorrect company information

Nuvectra Corporation News and Updates

Report incorrect company information